Oct 19, 2026Trial update3 fact check notes

Novo Nordisk registers real-world semaglutide study with Eucalyptus in Australia

Novo Nordisk has listed a new observational trial tracking semaglutide use among Australian patients on a digital weight loss platform run by Eucalyptus Services.

"Semaglutide Health Outcomes and Patient Adherence on Digital Health Platforms in Australia" (SHAPED-AU, NCT07881770) is an observational study sponsored by Novo Nordisk A/S with Eucalyptus Services Pty Ltd as collaborator, status not yet recruiting. Enrollment is estimated at 10,000 participants¹, with an estimated start date of October 13, 2026 and estimated primary completion on February 28, 2028, as listed in the registry.

Fact check notes

Checker's noteThe claim that this was Novo Nordisk's 'lone registry update for the period' is not supported by the source, which contains no information about other registry filings or a defined reporting period.
Sentence removedNovo Nordisk's lone registry update for the period covers a new observational study in Australia, registered October 19, 2026.unsupported: The source document only describes this single study; it contains no information about other registry updates or confirms this was the 'lone' update for any period.
Sentence removedThe study aims to generate real-world evidence on the use of semaglutide in adults with overweight or obesity receiving care through a digital weight loss service programme in Australia.copied source wording

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.